Patents by Inventor John Knights

John Knights has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12378177
    Abstract: A method is described herein, comprising vaporizing a glycol material by thermal contact with a heating medium to form a vaporized glycol stream, increasing a pressure of the vaporized glycol stream to form a pressurized glycol stream, and increasing a temperature of the heating medium by thermally contacting the heating medium with the pressurized glycol stream.
    Type: Grant
    Filed: December 1, 2020
    Date of Patent: August 5, 2025
    Assignee: CAMERON INTERNATIONAL CORPORATION
    Inventors: David John Knight, Steven Langley, Bryan Bussell
  • Publication number: 20250235681
    Abstract: An ultrasonic probe is provided and includes a rollable probe head and an ultrasonic transducer. The rollable probe head is configured to couple sound energy emitted from the ultrasonic transducer to a working surface. The ultrasonic probe further includes a reservoir for containing a flowable substance. The rollable probe head is configured to dispense the flowable substance from the reservoir to the working surface when rotated. The probe head is configured to roll smoothly across a working surface, such as skin, smoothly whilst delivering an appropriate amount of flowable substance to the skin as it rolls.
    Type: Application
    Filed: October 4, 2022
    Publication date: July 24, 2025
    Inventor: Benjamin John KNIGHT-GREGSON
  • Publication number: 20250234999
    Abstract: Concealable panel-engagement apparatus (10) for attaching a panel (16) to opposing perimeter support surfaces (40a). The concealable panel-engagement apparatus (10) comprising at least one elongate support rack (12) which is receivable in a said panel (16). The elongate support rack (12) has a plurality of rack openings (22) and an end peg (18) extendable from the panel (16). A rack driver (14) is also provided which is engageable with one or more of the rack openings (22) to move the end peg (18) into a said perimeter support surface (40a) adjacent to the panel (16).
    Type: Application
    Filed: March 3, 2023
    Publication date: July 24, 2025
    Inventor: Stephen John KNIGHT
  • Patent number: 12364335
    Abstract: Concealable panel-engagement apparatus (10) for attaching a panel (16) to opposing perimeter support surfaces (40a). The concealable panel-engagement apparatus (10) comprising at least one elongate support rack (12) which is receivable in a said panel (16). The elongate support rack (12) has a plurality of rack openings (22) and an end peg (18) extendable from the panel (16). A rack driver (14) is also provided which is engageable with one or more of the rack openings (22) to move the end peg (18) into a said perimeter support surface (40a) adjacent to the panel (16).
    Type: Grant
    Filed: March 3, 2023
    Date of Patent: July 22, 2025
    Inventor: Stephen John Knight
  • Publication number: 20250205434
    Abstract: A syringe assembly includes a syringe barrel (12) having a proximal end and a distal end, a needle hub (20) supporting the needle and coupled to the distal end of the syringe barrel (12). A moveable shield (36) is included for sliding from a first position where the needle is exposed a first length, a second position where the needle is exposed a second length less than said first length, and a third position covering a distal end of the needle. A locking mechanism (48, 86) is included to retain the shield in the second position while enabling the shield to slide to the third position, and to lock the shield in the third position to prevent re-use of the syringe.
    Type: Application
    Filed: March 17, 2025
    Publication date: June 26, 2025
    Applicant: Becton, Dickinson and Company
    Inventors: John KNIGHT, Jeffrey REED, Scott TOWNSEND, Patrick MCCALLUM
  • Patent number: 12251543
    Abstract: A syringe assembly includes a syringe barrel (12) having a proximal end and a distal end, a needle hub (20) supporting the needle and coupled to the distal end of the syringe barrel (12). A moveable shield (36) is included for sliding from a first position where the needle is exposed a first length, a second position where the needle is exposed a second length less than said first length, and a third position covering a distal end of the needle. A locking mechanism (48, 86) is included to retain the shield in the second position while enabling the shield to slide to the third position, and to lock the shield in the third position to prevent re-use of the syringe.
    Type: Grant
    Filed: July 29, 2020
    Date of Patent: March 18, 2025
    Assignee: Becton, Dickinson and Company
    Inventors: John Knight, Jeffrey Reed, Scott Townsend, Patrick McCallum
  • Patent number: 12233051
    Abstract: The disclosure provides methods of treating a patient having primary hyperoxaluria or idiopathic hyperoxaluria comprising administering a therapeutically effective amount of compound of the formula and pharmaceutically acceptable salts, solvates, and hydrates thereof to the patient. The variables, e.g. ring A, n, R, R3, R10, X, Y, and Z are defined herein. These compounds act as lactate dehydrogenase inhibitors and are useful inhibiting the conversion of glyoxylate to oxalate. When administered to a patient having a disease or disorder associated with elevated oxalate levels, such as PH type 1, type 2, or type 3 or idiopathic hyperoxaluria the compounds prevent or substantially reduce the amount and buildup of oxalate the patient's kidneys, bladder, urinary tract and other parts of the patient's body.
    Type: Grant
    Filed: July 14, 2023
    Date of Patent: February 25, 2025
    Assignees: VANDERBILT UNIVERSITY, THE UAB RESEARCH FOUNDATION, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Matthew Hall, Daniel J. Urban, John Knight, Ross Holmes, Kyle David Wood, Alex Waterson, Victor M. Darley-Usmar, Leonard M. Neckers
  • Publication number: 20250025717
    Abstract: A device for stimulating vitamin D production in a tissue. The device comprises a UV-B light source configured to emit light with a wavelength between 280 nm and 320 nm; and at least one tissue penetrating member optically coupled to the UV-B light source to deliver light emitted from the UV-B light source into the tissue, wherein the at least one tissue penetrating member has a length greater than or equal to 10 ?m and less than 10 mm.
    Type: Application
    Filed: December 1, 2022
    Publication date: January 23, 2025
    Inventor: Benjamin John KNIGHT-GREGSON
  • Publication number: 20250017953
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the LDHA gene, as well as methods of inhibiting expression of LDHA, methods of inhibiting LDHA and HAO1, and methods of treating subjects that would benefit from reduction in expression of LDHA, such as subjects having an oxalate pathway-associated disease, disorder, or condition, using such dsRNA compositions.
    Type: Application
    Filed: April 17, 2024
    Publication date: January 16, 2025
    Inventors: David Erbe, Abigail Liebow, Kevin Fitzgerald, Gregory Hinkle, Kyle David Wood, Ross Philip Holmes, John Knight
  • Publication number: 20240383849
    Abstract: The invention relates to a co-crystal or salt comprising psilocybin and a co-former. The co-crystal or salt is useful in methods of treating or preventing a disease or condition selected from depression, anxiety, death anxiety, demoralization, adjustment disorders, hopelessness, suicidal ideation, desire for hastened death, cocaine-related disorders, opioid-related disorders and stimulant-related disorders in a patient. A kit comprising the co-crystal or salt is also described.
    Type: Application
    Filed: June 28, 2024
    Publication date: November 21, 2024
    Inventors: John KNIGHT, Talbir AUSTIN
  • Publication number: 20240350491
    Abstract: Aspects of the disclosure are directed to methods and compositions for treating or preventing an allergic airway disease in a subject in need thereof. Certain aspects relate to treatment with an effective amount of a composition comprising one or more Dickkopf-1 (Dkk-1) inhibitors and/or one or more additional allergic airway disease therapies. Further aspects relate to methods of reducing airway inflammation, reducing airway hyper-responsiveness, and/or inhibiting an adaptive or innate immune response in the airway of a subject comprising administering to the subject an effective amount of a composition comprising one or more Dkk-1 inhibitors and/or one or more additional allergic airway disease therapies.
    Type: Application
    Filed: September 8, 2022
    Publication date: October 24, 2024
    Inventors: John Knight, Yifan Wu, David Corry
  • Patent number: 12060328
    Abstract: The invention relates to a co-crystal or salt comprising psilocybin and a co-former. The co-crystal or salt is useful in methods of treating or preventing a disease or condition selected from depression, anxiety, death anxiety, demoralization, adjustment disorders, hopelessness, suicidal ideation, desire for hastened death, cocaine-related disorders, opioid-related disorders and stimulant-related disorders in a patient. A kit comprising the co-crystal or salt is also described.
    Type: Grant
    Filed: March 3, 2023
    Date of Patent: August 13, 2024
    Assignee: RESET PHARMACEUTICALS, INC.
    Inventors: John Knight, Talbir Austin
  • Publication number: 20230372308
    Abstract: The disclosure provides methods of treating a patient having primary hyperoxaluria or idiopathic hyperoxaluria comprising administering a therapeutically effective amount of compound of the formula and pharmaceutically acceptable salts, solvates, and hydrates thereof to the patient. The variables, e.g. ring A, n, R, R3, R10, X, Y, and Z are defined herein. These compounds act as lactate dehydrogenase inhibitors and are useful inhibiting the conversion of glyoxylate to oxalate. When administered to a patient having a disease or disorder associated with elevated oxalate levels, such as PH type 1, type 2, or type 3 or idiopathic hyperoxaluria the compounds prevent or substantially reduce the amount and buildup of oxalate the patient's kidneys, bladder, urinary tract and other parts of the patient's body.
    Type: Application
    Filed: July 14, 2023
    Publication date: November 23, 2023
    Inventors: Matthew HALL, Daniel J. URBAN, John KNIGHT, Ross HOLMES, Kyle David WOOD, Alex WATERSON, Victor M. DARLEY-USMAR, Leonard M. NECKERS
  • Patent number: 11752138
    Abstract: The disclosure provides methods of treating a patient having primary hyperoxaluria or idiopathic hyperoxaluria comprising administering a therapeutically effective amound of compound of the formula and pharmaceutically acceptable salts, solvates, and hydrates thereof to the patient. The variables, e.g. ring A, n, R, R3, R10, X, Y, and Z are defined herein. These compounds act as lactate dehydrogenase inhibitors and are useful inhibiting the conversion of glyoxylate to oxalate. When administered to a patient having a disease or disorder associated with elevated oxalate levels, such as PH type 1, type 2, or type 3 or idiopathic hyperoxaluria the compounds prevent or substantially reduce the amount and buildup of oxalate the patient's kidneys, bladder, urinary tract and other parts of the patient's body.
    Type: Grant
    Filed: May 17, 2021
    Date of Patent: September 12, 2023
    Assignees: VANDERBILT UNIVERSITY, THE UAB RESEARCH FOUNDATION, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Matthew Hall, Daniel J. Urban, John Knight, Ross Holmes, Kyle David Wood, Alex Waterson, Victor M. Darley-Usmar, Leonard M. Neckers
  • Publication number: 20230279032
    Abstract: The invention relates to a co-crystal or salt comprising psilocybin and a co-former. The co-crystal or salt is useful in methods of treating or preventing a disease or condition selected from depression, anxiety, death anxiety, demoralization, adjustment disorders, hopelessness, suicidal ideation, desire for hastened death, cocaine-related disorders, opioid-related disorders and stimulant-related disorders in a patient. A kit comprising the co-crystal or salt is also described.
    Type: Application
    Filed: March 3, 2023
    Publication date: September 7, 2023
    Inventors: JOHN KNIGHT, TALBIR AUSTIN
  • Publication number: 20230212118
    Abstract: Described herein is a method for obtaining a selective estrogen receptor degrader, and compounds used in preparing the selective estrogen receptor degrader.
    Type: Application
    Filed: April 21, 2021
    Publication date: July 6, 2023
    Inventors: Peter Qinhua Huang, Sayee Gajanan Hegde, Kevin Duane Bunker, John Knight, Joseph Robert Pinchman, Aditya Krishnan Unni, Rakesh Kumar Sit, Shuguang Zhu, Chad Daniel Hopkins, Ian Scott
  • Publication number: 20230202978
    Abstract: The invention relates to a co-crystal or salt comprising psilocin and a co-former. The co-crystal or salt is useful in methods of treating or preventing a disease or condition selected from depression, anxiety, death anxiety, demoralization, adjustment disorders, hopelessness, suicidal ideation, desire for hastened death, cocaine-related disorders, opioid-related disorders and stimulant-related disorders in a patient. A kit comprising the co-crystal or salt is also described.
    Type: Application
    Filed: March 3, 2023
    Publication date: June 29, 2023
    Inventors: John Knight, Talbir Austin
  • Publication number: 20230002298
    Abstract: A method is described herein, comprising vaporizing a glycol material by thermal contact with a heating medium to form a vaporized glycol stream, increasing a pressure of the vaporized glycol stream to form a pressurized glycol stream, and increasing a temperature of the heating medium by thermally contacting the heating medium with the pressurized glycol stream.
    Type: Application
    Filed: December 1, 2020
    Publication date: January 5, 2023
    Inventors: David John Knight, Steven Langley, Bryan Bussell
  • Publication number: 20220389006
    Abstract: Salts of Compound A and forms described herein are estrogen receptor alpha modulators. Such salts and/or forms can be are useful for treating diseases or conditions that are estrogen receptor alpha dependent and/or estrogen receptor alpha mediated, including conditions characterized by excessive cellular proliferation, such as breast cancer.
    Type: Application
    Filed: November 2, 2020
    Publication date: December 8, 2022
    Inventors: Peter Qinhua Huang, Sayee Gajanan Hegde, Kevin Duane Bunker, John Knight, Deborah Helen Slee
  • Publication number: 20220273888
    Abstract: A syringe assembly includes a syringe barrel (12) having a proximal end and a distal end, a needle hub (20) supporting the needle and coupled to the distal end of the syringe barrel (12). A moveable shield (36) is included for sliding from a first position where the needle is exposed a first length, a second position where the needle is exposed a second length less than said first length, and a third position covering a distal end of the needle. A locking mechanism (48, 86) is included to retain the shield in the second position while enabling the shield to slide to the third position, and to lock the shield in the third position to prevent re-use of the syringe.
    Type: Application
    Filed: July 29, 2020
    Publication date: September 1, 2022
    Applicant: Becton,Dickinson and Company
    Inventors: John KNIGHT, Jeffrey REED, Scott TOWNSEND, Patrick MCCALLUM